MAIA Biotechnology Files 8-K for Regulatory and Financial Reporting
Ticker: MAIA · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
TL;DR
MAIA Bio filed an 8-K for standard reporting - no major news.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on June 3, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial details or material events beyond the reporting of these items.
Why It Matters
This 8-K filing indicates MAIA Biotechnology is fulfilling its regulatory obligations for reporting financial statements and exhibits, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any new risks or material changes.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- June 3, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Chicago, IL (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by MAIA Biotechnology, Inc.?
The primary purpose of this 8-K filing is to report information under Regulation FD and to file financial statements and exhibits.
On what date was this 8-K report filed?
The 8-K report was filed on June 3, 2024.
In which state is MAIA Biotechnology, Inc. incorporated?
MAIA Biotechnology, Inc. is incorporated in Delaware.
What is the address of MAIA Biotechnology, Inc.'s principal executive offices?
The principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Does this filing disclose any specific new business developments or financial results?
This filing primarily serves to report financial statements and exhibits and does not appear to disclose specific new business developments or detailed financial results beyond what is required for these filings.
Filing Stats: 800 words · 3 min read · ~3 pages · Grade level 13.2 · Accepted 2024-06-03 16:05:55
Filing Documents
- d728441d8k.htm (8-K) — 25KB
- d728441dex991.htm (EX-99.1) — 13KB
- d728441dex992.htm (EX-99.2) — 20KB
- g728441ex99_1s1g1.jpg (GRAPHIC) — 192KB
- g728441ex99_2s10g1.jpg (GRAPHIC) — 61KB
- g728441ex99_2s11g1.jpg (GRAPHIC) — 65KB
- g728441ex99_2s12g1.jpg (GRAPHIC) — 52KB
- g728441ex99_2s13g1.jpg (GRAPHIC) — 73KB
- g728441ex99_2s14g1.jpg (GRAPHIC) — 76KB
- g728441ex99_2s15g1.jpg (GRAPHIC) — 73KB
- g728441ex99_2s16g1.jpg (GRAPHIC) — 51KB
- g728441ex99_2s17g1.jpg (GRAPHIC) — 32KB
- g728441ex99_2s1g1.jpg (GRAPHIC) — 52KB
- g728441ex99_2s2g1.jpg (GRAPHIC) — 92KB
- g728441ex99_2s3g1.jpg (GRAPHIC) — 59KB
- g728441ex99_2s4g1.jpg (GRAPHIC) — 54KB
- g728441ex99_2s5g1.jpg (GRAPHIC) — 81KB
- g728441ex99_2s6g1.jpg (GRAPHIC) — 91KB
- g728441ex99_2s7g1.jpg (GRAPHIC) — 83KB
- g728441ex99_2s8g1.jpg (GRAPHIC) — 59KB
- g728441ex99_2s9g1.jpg (GRAPHIC) — 81KB
- 0001193125-24-153019.txt ( ) — 2025KB
- maia-20240603.xsd (EX-101.SCH) — 3KB
- maia-20240603_lab.xml (EX-101.LAB) — 18KB
- maia-20240603_pre.xml (EX-101.PRE) — 11KB
- d728441d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 3, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3